Research
Hormonal
Tirzepatide has potential impacts on diabetes, obesity, NASH, and cardiovascular risks.
Tirzepatide may be beneficial for patients with diabetes and associated comorbidities.
StrongSupportsmedium confidence
its potential impact on diabetes, obesity, NASH, and cardiovascular risks.
Why this rating
Based on clinical trials mentioned in the abstract.
Source
Revolutionizing diabetes care: unveiling tirzepatide’s potential in glycemic control and beyond
Aayushi Sood et al. · Expert Review of Clinical Pharmacology · 2024
DOI 10.1080/17512433.2024.2310070
reviewCited 3×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →